Search research articles
Contact Us
Filters
Showing results (251-260 of 272) with videos related to
Page
of 28
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Laurie H Sehn, Andre Goy, Fritz C Offner, et al.
Cancer Research
|
September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
Damian J Green, Shani L Frayo, Yukang Lin, et al.
Cancer Research
|
December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies
Damian J Green, Nural N Orgun, Jon C Jones, et al.
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Blood
|
October 26, 2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
O W Press, J F Eary, T Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
Ryan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology
|
October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma
Ryan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
The Lancet. Haematology
|
April 3, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma
S A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation
|
July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma
Sherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 272) with videos related to
Sort By:
Page
of 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2015
Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
Laurie H Sehn, Andre Goy, Fritz C Offner, et al.
Cancer Research
|
September 4, 2016
Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers
Damian J Green, Shani L Frayo, Yukang Lin, et al.
Cancer Research
|
December 28, 2013
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies
Damian J Green, Nural N Orgun, Jon C Jones, et al.
The Lancet. Oncology
|
May 1, 2015
Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
Maria Corinna A Palanca-Wessels, Myron Czuczman, Gilles Salles, et al.
Blood
|
October 26, 2000
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
O W Press, J F Eary, T Gooley, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2013
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation
Ryan D Cassaday, Katherine A Guthrie, Elizabeth L Budde, et al.
British Journal of Haematology
|
October 13, 2015
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma
Ryan D Cassaday, Philip A Stevenson, Theodore A Gooley, et al.
The Lancet. Haematology
|
April 3, 2019
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser, Ian W Flinn, Ranjana Advani, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 9, 2015
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma
S A Graf, P A Stevenson, L A Holmberg, et al.
Bone Marrow Transplantation
|
July 26, 2020
<sup>90</sup>Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma
Sherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, et al.
Page
of 28